Physician profile
Micah Boyer
NPI 1306289087
$1,233.63
in general payments reported to CMS, 2019-2025
24 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $12.20 · 2021: $120 · 2022: $312 · 2023: $205 · 2024: $79.88 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $157.30 | 2022-2024 | Ubrelvy |
| Novo Nordisk INC | $128.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merz North America, INC. | $112.22 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.14 | 2019-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $100.52 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $96.99 | 2019-2022 | |
| Amgen INC. | $84.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $43.61 | 2021-2022 | |
| Galderma Laboratories, L.P. | $42.04 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $33.40 | 2022 | |
| Merck Sharp & Dohme LLC | $32.00 | 2019-2021 | |
| Pfizer INC. | $31.66 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $25.32 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.30 | 2024 | Rexulti, Abilify Asimtufii |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.98 | 2021 | |
| Exact Sciences Corporation | $20.19 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $18.95 | 2023 | Freestyle Libre 3 |
| Viatris Specialty LLC | $17.68 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $17.33 | 2024 | Voquezna |
| Astellas Pharma US INC | $16.86 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.83 | 2022 | |
| Corium, LLC | $14.74 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.